Cheap Cholesterol Drugs Could Prolong Life for Motor Neurone Disease Patients
A groundbreaking new study has revealed that inexpensive, commonly prescribed medications, including statins used for high cholesterol, could help people with motor neurone disease live longer. The research, published in the Lancet Digital Health journal, represents the largest investigation to date into drug repurposing for ALS, one of the primary forms of MND.
Motor neurone disease is a progressive neurodegenerative condition that causes severe muscle weakness, often leading to loss of mobility and respiratory function. Currently, there is no cure, and most patients survive only three to five years following diagnosis.
Major Analysis of Veteran Health Records
Researchers from Stanford University School of Medicine in the United States conducted an extensive analysis of medical records from 11,003 American veterans diagnosed with amyotrophic lateral sclerosis between 2009 and 2019. Their examination revealed a significant pattern: patients who had been prescribed certain existing medications for other conditions appeared to experience prolonged survival.
In total, the study identified 18 different medications that were associated with extended life expectancy in ALS patients. The most notable among these were statins, typically prescribed to manage high cholesterol, and alpha blockers, also known as alpha adrenergic receptor antagonists, which are commonly used to treat urinary symptoms in men with enlarged prostates.
Potential for Immediate Clinical Impact
Lead author Professor Richard Reimer from Stanford University emphasized the potential significance of these findings. "Currently there are no truly effective treatments for ALS and people with the disease only live between three and five years after they have been diagnosed," he stated. "Our findings suggest that treatment with statins and alpha blockers might prolong survival for individuals with ALS."
Professor Reimer highlighted several advantages of these potential treatments: "Both statins and alpha blockers are generally well tolerated and available in inexpensive generic forms. This could make them accessible options if further research confirms their benefits."
The researchers noted that this study represents a novel approach to finding treatments for ALS. "To our knowledge, this is the largest study to identify new ALS treatment candidates through drug repurposing and the first to be based on electronic health records," the authors wrote in their published paper.
Next Steps in Research
While the observational study shows promising associations, the researchers caution that more investigation is needed to understand the underlying mechanisms. "The next steps will be determining why these associations exist and who may benefit from the treatments," explained Professor Reimer.
Key questions that need answering include whether statins affect ALS survival by lowering cholesterol levels, and whether they are only beneficial for patients with elevated cholesterol. The researchers also need to determine if alpha blockers' potential benefits relate to their primary function or involve other biological pathways.
Once these mechanisms are better understood, the research team hopes to conduct formal placebo-controlled clinical trials to definitively confirm whether these repurposed drugs can extend life for MND patients. Such trials would provide the evidence needed for potential changes to treatment guidelines.
This research offers new hope for the approximately 5,000 people living with MND in the United Kingdom and many more worldwide. The possibility of extending survival using existing, affordable medications represents a significant development in the fight against this devastating disease.
